Vivozon Pharmaceuticals

Vivozon Pharmaceutical is a South Korean biopharmaceutical company specializing in the development of innovative small molecule therapeutics for central nervous system (CNS) diseases and pain management. The company's core technology is its proprietary multi-target drug discovery platform, which utilizes a bait-target approach and ex vivo phenotypic screening to identify synergistic multi-receptor mechanisms. Vivozon's lead product, Unafra (opiranserin / VVZ-149), is a first-in-class non-narcotic analgesic that simultaneously targets GlyT2 and 5-HT2A; it received approval from South Korea's Ministry of Food and Drug Safety (MFDS) in December 2024 for moderate-to-severe postoperative pain. The company is also advancing VVZ-2471, an oral dual mGluR5 and 5-HT2A antagonist, in Phase 2 trials for postherpetic neuralgia and Phase 1 trials for opioid use disorder, alongside a broader pipeline targeting schizophrenia, depression, and neurodegenerative diseases.